Sanofi has begun promoting Acomplia to doctors even though it is not yet approved by the FDA—kinda, sorta. What’s actually happening is that part of Sanofi’s diabetes sales force is briefing docs on “cardiometabolic risk, intra-abdominal adiposity and the endo-cannabinoid system.” (Those are posh med school words that mean “fat people.”)
According to a copy of a detail piece that a source kindly sent me (see download below), “increased activity of the endocannabinoid system has been shown to have an effect on: food intake, energy expenditure, and regulation of body weight.”
If only Sanofi had a drug that could regulate the endocannabinoid system. Sigh.
Oh, wait! It does! It’s called Acomplia! (Or maybe it’s called Zimulti?) Fancy that! What an amazing coincidence! According to this Sanofi press release, “Acomplia acts to decrease the overactivity of the endocannabinoid system”!
Of course, because Acomplia is not yet approved in the U.S. Sanofi sales reps aren’t allowed to mention the words “Acomplia,” “Zimulti” or “Rimonabant.” The drug goes before the FDA in June. Clearly, the Sanofites think they’ve got it right this time around, having been stalled at the FDA for some months.
The issues causing headaches for Sanofi right now: Whether the FDA will give them an indication for “obesity management,” (which likely won’t be reimbursed by insurance companies), “metabolic syndrome” (meaning a package of symptoms including intractable obesity that insurance companies would be likely to reimbuirse for), or Type 2 diabetes (which would definitely be covered).
Acomplia Report is predicting it will get obesity management only. Sanofi was expecting Acomplia to be a blockbuster, but such an unreimbursible indication would put a severe crimp on sales if patients have to pay for it themselves.
Some thoughts on pre-approval promotions: The FDA clearly prohibits companies from touting a drug that is unapproved by the FDA. But it doesn’t prohibit them from discussing diseases and conditions generally, even if the only reason they’re talking about such a disease is that they have an upcoming pill for it.
From a layperson’s perspective, then, unbranded pre-approval promotions are identical to promoting “misbranded” (to use the FDA’s technical term) unapproved drugs, with the two exceptions that the promotion takes place before, rather than after, approval and that the name of the drug is not used. Seems like its walking on the legal line ... a technical difference is not the same as an ethical one ...
Such pre-approval detailing is common, a source tells me, and indicates that the company believes it is between 6 and 2 months from receiving an “approved” letter from the feds.
Perhaps Sanofi has developed some good answers regarding concerns that Acomplia makes its users depressed and anxious.
Acomplia (Rimonabant) is an anorectic anti obesity drug. It is a CB1 cannabinoid receptor antagonist. Acomplia (Rimonabant) has been found to stop food craving enough to help people lose weight, and could also help curb other unhealthy urges, such as smoking. - http://acomplia.weightloss.lt
Posted by: acomplia | January 17, 2008 at 07:42 AM
Acomplia (Rimonabant / Zimulti) is the new weight loss medication breakthrough from Sanofi-Aventis , exceeding Phentermine in it’s ability to help you lose the weight!
http://www.nordmed.com/acomplia-brand-medication.php
It is a CB1 cannabinoid receptor antagonist ,and Its main avenue of effect is reduction in appetite. Acomplia acts by obstructing the receptors, which control the food intake and energy expenditure - Thus resulting in reduced appetite.
http://www.nordmed.com/generic-acomplia-medication.php
Posted by: acomplia online | July 19, 2008 at 04:19 AM
http://www.ipetitions.com/petition/buyacomplia/
BUy Acomplia Online here at cheap prices
Posted by: Acomplia Online | October 21, 2008 at 06:45 AM
Trade shows are a great way to advertise. All you need is an attractive exhibition stand to catch the attention of attendees.
Posted by: Banner Stands | September 29, 2009 at 07:30 PM
Interesting article I like to know more about this topic is a nice site and important to know.
Posted by: Generic viagra | October 27, 2009 at 03:00 PM
These kind of medicines can be pretty riski for our children.
Posted by: Caffeine Addiction | November 02, 2009 at 10:19 AM
Great post I want to know the benefits of this Promotion for Acomplia because I want to have but I need to know everythings.
Posted by: Internet Pharmacy | November 03, 2009 at 12:15 PM
Acomplia is is great medicine even used in ill children or adults.
Posted by: Buy Generic Viagra | November 05, 2009 at 08:19 AM
hello thanks for post this information about Sanofi Doing Pre-Launch Promotion for Acomplia (or Zimulti or Whatever It's Called This Week) I think that is information is very useful
Posted by: Generic Viagra | November 30, 2009 at 05:44 PM
hey buddy amazing blog about Sanofi Doing Pre-Launch Promotion for Acomplia (or Zimulti or Whatever It's Called This Week) this information is very useful!!
Posted by: Generic Viagra | December 03, 2009 at 08:26 AM
nice and important blog about Sanofi Doing Pre-Launch Promotion for Acomplia (or Zimulti or Whatever It's Called This Week) thanks for sharing!!
Posted by: generic caverta | December 16, 2009 at 11:39 AM
this crap really works ?
Posted by: buy viagra | January 11, 2010 at 03:58 PM